Tier 1 – validated biomarkers ○Markers with strong performance data that have successfully completed initial validation studies in subsequent reports or in a multi-centre setting with more than 120 patients.

Tier 2 – high-performing biomarkers ○Markers with good performance data that have not completed validation studies. Markers in this category are further divided into subgroups depending on the intended use and number of patients. ▪2A: Specificity and sensitivity >80%, or specificity or sensitivity >85%*, with an intended use of early detection, prediction or differential diagnosis and greater than 120 subjects ▪2B: Specificity and sensitivity >80%, or specificity or sensitivity >85%*, with an intended use of early detection, prediction or differential diagnosis and less than 120 subjects ▪2C: Specificity and sensitivity >80%, or specificity or sensitivity >85%*, with an intended use of diagnosis ▪2D: Same criteria as Tier 2A–C, with markers having applications in both blood and CSF.

Tier 3 – promising candidate biomarkers ○Innovative markers with promising performance data but have not yet produced higher performance results in clinical settings.

^*Along with an adequate, non-zero score on the other parameter